source
- Gate CEO sees expanded $870M pact with Lilly as ‘vote of confidence’ in biotech’s platformEli Lilly has been pushing at an open door by tacking on $870 million in biobucks to its existing collaboration with Gate Bioscience.
- Key criteria for selecting a biologics CDMO: reliability, cost, technology and partnership fitChoosing the right contract development and manufacturing organization is a strategic move for biotech and biopharma firms, as it can speed development and lower regulatory risk. The top priority…